Physician profile
Debra Ann Durham
NPI 1386646677
$607.53
in general payments reported to CMS, 2019-2025
16 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.74 · 2020: $138 · 2021: $193 · 2024: $110 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $94.36 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $94.31 | 2020-2025 | Trintellix |
| Pfizer INC. | $61.77 | 2021 | |
| Abbvie INC. | $57.08 | 2024 | |
| Exact Sciences Corporation | $54.38 | 2024-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $45.92 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.35 | 2021 | |
| Sanofi-Aventis U.S. LLC | $31.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.23 | 2025 | Zoryve |
| Esperion Therapeutics, INC. | $20.16 | 2025 | Nexletol |
| Phadia US INC. | $19.73 | 2021 | |
| Ardelyx, INC. | $18.52 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.73 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.31 | 2020 | |
| Glaxosmithkline, LLC. | $11.91 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Durham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.